INTRODUCTION
It has been demonstrated in vivax malaria that the therapeutic response to quinine is closely related to the mean plasma quinine concentration achieved during a standard testing procedure (1) . In addition, the susceptibility of the erythrocytic phase to quinine has been shown to be a stable characteristic of the McCoy strain of P. zuvax and to differ quantitatively from that of the Chesson strain.
The human malarias due to the two other common species of plasmodium differ from vivax malaria in their biological and clinical characteristics and in their responses to chemotherapeutic agents. Therefore, it seemed advisable to determine their susceptibilities to quinine as a basis for the comparative assay of other antimalarials. However, infections due to P. malariae proved to be impractical for therapeutic testing because of their long incubation periods, the low density of peripheral 1 The work described in this paper was parasitemia, and the somewhat erratic course of the disease. Systematic studies were discontinued in view of these difficulties, together with the lesser importance of quartan malaria.
The present paper is concerned with studies of the susceptibility to quinine of the erythrocytic phase of two strains of falciparum malaria. All patients used in this study were neuro-syphilitics who presented no medical contraindication to therapeutic malaria. In general, the patients were those whose racial extraction or history of previous malaria made them unsuitable as experimental subjects in the vivax studies.
BLOOD-INDUCED MCCLENDON FALCIPARUM MALARIA
Falciparum (McClendon) 6 malaria, induced by an intravenous inoculum of 500,000 erythrocytic parasites, is characterized by a prepatent period of from two to 12 days (average five days). This is followed by an irregular, sustained fever and the rapid development of peripheral parasitemia which frequently reaches 50,000 per cu. mm. or higher by the second or third day after the first appearance of parasites in thick film preparations. In general, the onset of fever coincides with the first appearance of parasites in thick blood films. Only rarely does a patient achieve a parasite count as high as 10,000 per cu. mm. without fever during a primary attack.
Because excessive parasitemia and prolonged fever constitute a hazard to life in falciparum malaria, no deliberate attempt was made to observe The observation period subsequent to therapy began on the day following the last effective plasma drug level. In the event of the complete disappearance of parasites and fever, the follow-up period was extended to at least 21 days, this interval being necessary to include the majority of renewals of clinical activity due to persistence of an erythrocytic phase. If, at the end of this period, there had been no evidence of renewed activity, reinoculation with one million parasites was performed and the patient followed until the recurrence of parasitemia. Therapeutic results were classified in three groups, as previously described for vivax infections (1).
The susceptibility of blood-induced McClendon falciparum malaria to quinine The first series of observations involved the administration of quinine to 15 patients with blood-induced falciparum (McClendon) malaria (Table I) . Stable plasma quinine concentrations were maintained for four days. Mean plasma quinine concentrations ranged from 2.1 to 10.4 mg. per liter. However, dosage regimens close to the upper limit of tolerance, when restricted to four days, result only in temporary therapeutic effects (Class II).
Therefore, therapeutic tests were performed in an additional 13 subjects in whom the period of effective plasma quinine concentration was extended to six days (Table II) . Mean plasma drug concentrations ranged from 2.9 to 8.7 mg. per liter. Mean plasma quinine concentrations of 5.6 mg. per liter or higher, maintained for six days, consistently produced a permanent disappearance Further evidence of the importance of'the duration of therapy in evaluating the quinine susceptibility of the erythrocytic phase of McClendon falciparum was obtained by a study of six patients in whom plasma quinine concentrations were maintained for eight days (Table III) The variation in quinine-susceptibility between different strains of vivax malaria (1) prompted an examination of the antimalarial effect of quinine against another strain of P. falciparum.7 Sixteen patients were inoculated with Costa falciparum. The course of fever and parasitemia of Costa falciparum malaria is similar to that of the McClendon strain. In general, neither excessive parasitemia nor prolonged fever occurred as frequently in Costa falciparum infections as in McClendon malaria. Except for the strain of parasite used, the therapeutic testing procedure was the same as that previously described ( 1 ). Plasma quinine concentrations in the first group were maintained for six days.
Examination of the data in Table IV reveals that quinine administered for six days in nearly maximum tolerated doses does not generally produce a permanent interruption of the disease (Class III effect). There-is no consistent re- (2) .
It is pertinent to note that resistance to the action of quinine is not necessarily related to the severity or virulence of the clinical disease. Costa falciparum, although more resistant to quinine than the McClendon strain, is nevertheless far less hazardous to life.
It is not intended that the appraisal of drug activity in blood-induced falciparum should replace studies utilizing vivax malaria. The two procedures are complementary in that they yield information on the comparative effectiveness of an antimalarial agent in both types of infection. It should be appreciated that, due to an apparent lack of a persisting tissue phase in falciparum malaria, the termination of the erythrocytic phase is tantamount to a cure. CONCLUSIONS 1. The therapeutic response of blood-induced McClendon falciparum malaria to quinine has been shown to be related to the plasma quinine concentration and the duration of therapy, both of which factors are amenable to quantitative definition.
2. Therefore, blood-induced malaria due to this strain should provide a suitable test object for the quantitative appraisal of the relative suppressive activities of antimalarial agents.
3. As in vivax malaria, the quinine-susceptibility of the erythrocytic phase differs in various strains of P. falciparum. Costa falciparum infections are more resistant to quinine than are those due to the McClendon strain.
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